P/E ratio for Spectrum Pharmaceuticals (SPPI)
P/E ratio as of April 2024 (TTM): -2.86
According to Spectrum Pharmaceuticals 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -2.86111. At the end of 2022 the company had a P/E ratio of -0.8605.
P/E ratio history for Spectrum Pharmaceuticals from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -0.8605 | -29.54% |
| 2021 | -1.22 | -53.45% |
| 2020 | -2.62 | -26.5% |
| 2019 | -3.57 | -52.69% |
| 2018 | -7.54 | -57.01% |
| 2017 | -17.5 | 268.35% |
| 2016 | -4.76 | -39.17% |
| 2015 | -7.83 | -17.51% |
| 2014 | -9.49 | 8.34% |
| 2013 | -8.76 | -226.99% |
| 2012 | 6.90 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 10.3 | -461.64% | 🇺🇸 USA |
 Novartis NVS | 24.8 | -965.09% | 🇨🇭 Switzerland |
 Pfizer PFE | 13.7 | -577.11% | 🇺🇸 USA |
 Abbott Laboratories ABT | 35.4 | -1,337.92% | 🇺🇸 USA |
 Biogen BIIB | 10.3 | -460.72% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 12.2 | -525.23% | 🇺🇸 USA |
 GlaxoSmithKline GSK | 11.2 | -492.08% | 🇬🇧 UK |
 Seagen
SGEN | -57.0 | 1,893.72% | 🇺🇸 USA |
 Curis CRIS | -1.52 | -46.80% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | -6.39 | 123.34% | 🇮🇱 Israel |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.